FimmCyte is a biotechnology company that engages in the research and treatment of chronic endometriosis disease.
FimmCyte has raised $1.1M in total funding. The most recent round was Convertible Note. The last funding was announced in February 2024.
FimmCyte's investors include BioInnovation Institute, Venture Kick, Innosuisse, BaseLaunch, InnoBooster.
FimmCyte is headquartered in Basel, Switzerland.
FimmCyte is a biotechnology company that engages in the research and treatment of chronic endometriosis disease.
FimmCyte is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"FimmCyte — Funding & Investors." VCBacked, February 28, 2024, https://www.vcbacked.co/company/fimmcyte. Accessed August 16, 2026.
VCBacked. (2024). FimmCyte — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/fimmcyte
{{cite web |title=FimmCyte — Funding & Investors |url=https://www.vcbacked.co/company/fimmcyte |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated